Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
By S. Schuster, J. Svoboda, E. Chong, S. Nasta, A. Mato, Ö. Anak, J. Brogdon, Iulian Pruteanu-Malinici, V. Bhoj, D. Landsburg and 6 more. New England Journal of Medicine, 2017
1,558 citations recorded by the source corpus.
Background Patients with diffuse large B‐cell lymphoma or follicular lymphoma that is refractory to or that relapses after immunochemotherapy and transplantation have a poor prognosis. High response rates have been reported with the use of T cells modified by chimeric antigen receptor (CAR) that target CD19 in B‐cell cancers, although data regarding B‐cell lymphomas are limited. Methods We used autologous T cells that express a CD19‐directed CAR (CTL019) to treat patients with diffuse large B‐cell lymphoma or follicular lymphoma that had relapsed or was refractory to previous treatments. Patients were monitored for response to treatment, toxic effects, the expansion and persistence of CTL019 cells in vivo, and immune recovery. Results A total of 28 adult patients with lymphoma received CTL019 cells, and 18 of 28 had a response (64%; 95% confidence interval [CI], 44 to 81). Complete remission occurred in 6 of 14 patients with diffuse large B‐cell lymphoma (43%; 95% CI, 18 to 71) and 10 of 14 patients with follicular lymphoma (71%; 95% CI, 42 to 92). CTL019 cells proliferated in vivo and were detectable in the blood and bone marrow of patients who had a response and patients who did not have a response. Sustained remissions were achieved, and at a median follow‐up of 28.6 months, 86% of patients with diffuse large B‐cell lymphoma who had a response (95% CI, 33 to 98) and 89% of patients with follicular lymphoma who had a response (95% CI, 43 to 98) had maintained the response. Severe cytokine‐release syndrome occurred in 5 patients (18%). Serious encephalopathy occurred in 3 patients (11%); 2 cases were self‐limiting and 1 case was fatal. All patients in complete remission by 6 months remained in remission at 7.7 to 37.9 months (median, 29.3 months) after induction, with a sustained reappearance of B cells in 8 of 16 patients and with improvement in levels of IgG in 4 of 10 patients and of IgM in 6 of 10 patients at 6 months or later and in levels of IgA in 3 of 10 patients at 18 months or later. Conclusions CTL019 cells can be effective in the treatment of relapsed or refractory diffuse large B‐cell lymphoma and follicular lymphoma. High rates of durable remission were observed, with recovery of B cells and immunoglobulins in some patients. Transient encephalopathy developed in approximately one in three patients and severe cytokine‐release syndrome developed in one in five patients. (Funded by Novartis and others; ClinicalTrials.gov number, NCT02030834.)
Subfields: Immunology, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/47cbdaceffd0b8474e7a95e749a3a313e3109ef2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019, background): “Overcoming treatment-related toxicities Therapeutic responses to CAR T cells in patients who otherwise have limited treatment options have been dramatic in some trials 2–5 , although at the cost of high rates of severe adverse events, including some fatalities.”
- Chimeric Antigen Receptor Therapy (2018, neutral): “maintained in 89% of patients who had a response Schuster et al.(45)”
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018, background): “These regimens include varying doses of cyclophosphamide alone [9–11,13,15,20,63], fludarabine and cyclophosphamide [8,9,12,13,15, 18–22,25,57], pentostatin and cyclophosphamide [14], bendamustine-based regimens [14,26], as well as several diseasespecific regimens determined by physician discretion ”